Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition) by Roots Analysis

Several approved therapeutic products, which are currently available as intravenous dosage forms, are being reformulated and evaluated for subcutaneous administration. Further, many existing drug delivery devices, including prefilled syringes, pen injectors, autoinjectors, needle-free injectors and large volume wearable injectors, have been / are being designed for subcutaneous administration of biologics.

To order this 530+ page report, which features 160+ figures and 190+ tables, please visit this –

The USD 180+ billion (by 2030) financial opportunity associated with subcutaneous biologics, affiliated drug delivery systems and subcutaneous formulation technology licensing deals, has been analyzed across the following segments:
 Phase of development
 Approved
 Pre-registration & Phase III
 Phase II & Phase II/III

 Type of molecule
 Cell and gene therapies
 Monoclonal antibodies
 Proteins
 Peptides (recombinant)
 Vaccines
 Others

 Target therapeutic area
 Autoimmune disorders
 Blood disorders
 Bone disorders
 Genetic disorders
 Metabolic disorders
 Neurological disorders
 Oncological disorders
 Respiratory disorders
 Others

 Type of drug delivery system
 Large volume wearable injectors
 Autoinjectors
 Prefilled syringes
 Needle-free injectors
 Drug reconstitution systems

To Request for sample –

 Revenues from licensing deals
 Upfront payments
 Milestone payments

 Key geographical regions
 North America
 Europe
 Asia Pacific
 Rest of the World

The Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030”report features the following companies, which we identified to be key players in this domain:
 Adocia
 Ajinomoto Bio-Pharma Services
 Arecor
 Alteogen
 Ascendis Pharma
 Avadel Pharmaceuticals

Leave a Reply

Your email address will not be published. Required fields are marked *